Inside J&J’s New Initiative to ‘Intercept’ Diseases

Ben Wiegand, Head of J&J's Disease Interception Accelerator. (Photo by Gene Smirnov.)

The pharmaceutical industry often develops drugs to manage diseases. But Johnson & Johnson posits a different model: What if you could identify people at risk and stave disease off?


Register For Free Access!

Share a little bit of info to have a look at this article, and get instant access to:

  • Case studies on how innovation happens in the world’s top companies
  • Our on-demand video library with 100+ hours of workshops and exclusive interviews with senior leaders
  • Assessment tests that give you an instant score
  • Curated content on getting an innovation program started


Want to become a member and get full access to everything? Learn more here.

If you are already a registered user or a member you can SIGN IN now.